129 related articles for article (PubMed ID: 26486708)
1. Response to Spellberg and Brass.
Solomkin JS; Hershberger E; Eckmann C
Clin Infect Dis; 2016 Feb; 62(4):526. PubMed ID: 26486708
[No Abstract] [Full Text] [Related]
2. Noninferiority Doesn't Mean Not Inferior.
Spellberg B; Brass EP
Clin Infect Dis; 2016 Feb; 62(4):525-6. PubMed ID: 26486703
[No Abstract] [Full Text] [Related]
3. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
Prabhu V; Foo J; Ahir H; Sarpong E; Merchant S
J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
[No Abstract] [Full Text] [Related]
6. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
7. Newer Intravenous Antibiotics in the Intensive Care Unit: Ceftaroline, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam.
Connor KA
AACN Adv Crit Care; 2016 Oct; 27(4):353-357. PubMed ID: 27959289
[No Abstract] [Full Text] [Related]
8. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
[TBL] [Abstract][Full Text] [Related]
10. Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.
Tamma SM; Hsu AJ; Tamma PD
Paediatr Drugs; 2016 Feb; 18(1):1-11. PubMed ID: 26645401
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.
Miller B; Popejoy MW; Hershberger E; Steenbergen JN; Alverdy J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4387-90. PubMed ID: 27139477
[TBL] [Abstract][Full Text] [Related]
12. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Popejoy MW; Long J; Huntington JA
BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
Gentile I; Buonomo AR; Maraolo AE; Scotto R; De Zottis F; Di Renzo G; Borgia G
J Antimicrob Chemother; 2017 Sep; 72(9):2678-2679. PubMed ID: 28575437
[No Abstract] [Full Text] [Related]
14. Oral or parenteral antibiotic treatment in serious infections.
Symonds J
Arch Dis Child; 1984 Jun; 59(6):501-3. PubMed ID: 6742870
[No Abstract] [Full Text] [Related]
15. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO
Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
[No Abstract] [Full Text] [Related]
16. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Eckmann C; Solomkin J
Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
[TBL] [Abstract][Full Text] [Related]
17. Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam.
Kullar R; Wagenlehner FM; Popejoy MW; Long J; Yu B; Goldstein EJ
J Antimicrob Chemother; 2017 Mar; 72(3):900-905. PubMed ID: 27999024
[TBL] [Abstract][Full Text] [Related]
18. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Vickery SB; McClain D; Wargo KA
Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of cefepime-tazobactam combination tested against clinical isolates of Enterobacteriaceae.
Kaur R; Gautam V; Singhal L; Ray P
J Antibiot (Tokyo); 2014 Aug; 67(8):603-4. PubMed ID: 24756027
[No Abstract] [Full Text] [Related]
20. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Maseda E; Aguilar L; Gimenez MJ; Gilsanz F
Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1311-24. PubMed ID: 25139127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]